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 INTRODUCTION
 Severe alcoholic hepatitis (SAH) presents within a spectrum 
ranging from decompensated liver disease with jaundice to life-
threatening liver failure associated with a signifi cant morbidity 
and early mortality that can attain 50–75% ( 1,2 ). It ranks among 
the most costly diseases during hospitalization ( 3 ). Th us the early 
detection of high-risk patients, prompt intervention, and accurate 
prognostic stratifi cation is crucial.
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 OBJECTIVES:  Prednisolone therapy increases the risk of infections in patients with severe alcoholic hepatitis 
(SAH). We evaluated whether the use of the Lille Model at day 4 (LM4) is useful to predict response 
to prednisolone compared with the classic day 7 (LM7) in order to limit a futile exposure to 
corticosteroids.
 METHODS:  We performed a retrospective analysis of a large multinational cohort of patients with SAH with 
Maddrey’s discriminant function (DF) ≥32. Response to corticosteroids was assessed with LM4 and 
LM7, according to the validated cutoff value (CUV>0.45). Receiver operating characteristics (ROC) 
curves were constructed to determine the optimal CUV for LM4 and to compare accuracy between 
LM4, LM7, MELD (Model for End-Stage Liver Disease), and ABIC (age, bilirubin, international 
normalized ratio, and creatinine). Logistic regression models were constructed to predict 28- and 
90-day mortality. Cox regression analysis was performed to assess long-term survival.
 RESULTS:  A total of 163 (62.7%) out of 260 patients received corticosteroids. The median DF for the patients 
treated with corticosteroids was 64.1 (47.9–81.3). Overall 90-day mortality was 35.9%. The median 
LM4 and LM7 for the patients who received treatment was 0.39 (0.19–0.83) and 0.36 (0.13–0.77). 
LM4 was a strong independent predictor of 28-day mortality (OR 25.4, (95% confi dence interval (CI) 
5.1–126.8),  P <0.001). By using LM4 with a CUV>0.45, 28- and 90-day survival was signifi cantly 
higher for responders (90% and 76%) than non-responders (66% and 40%),  P <0.001. Importantly, 
the area under the ROC curve for predicting mortality for LM4 was similar than the classic LM7 
(0.77 vs. 0.75, respectively:  P =0.558).
 CONCLUSIONS:  LM4 is as accurate as LM7 in predicting response to corticosteroids, as well as 28- and 90-day 
mortality. Assessing the effi cacy of prednisolone at an earlier time point can avoid a more prolonged 
futile use of this therapy.
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 Various prognostic models have been developed with the goal 
of determining which patients are at high risk of death. Maddrey’s 
discriminant function (DF) has been the standard surrogate for 
the assessment of disease severity and to guide treatment in AH. 
A cutoff  value (CUV) ≥32 identifi es subjects with an adverse 
prognosis, with a mortality of 20–30% during the fi rst month 
aft er AH onset and up to 40% at 6 months ( 4 ). Other prognostic 
models that evaluate the severity of the disease at baseline, such 
as the MELD (Model for end-stage liver disease), ABIC (age, 
bilirubin, international normalized ratio, and creatinine), and 
Glasgow alcoholic hepatitis score (GAHS), are all useful tools to 
determine the patient’s outcome ( 5–7 ). However, the time neces-
sary to prognosticate a therapeutic strategy and response is cru-
cial in order to avoid damage from intervening too early or too 
late and to guide therapy in patients at high risks of short-term 
mortality ( 8 ).
 Prednisolone continues to be the mainstay of treatment for 
patients with SAH, being the only treatment demonstrating mod-
est improvement in survival at 28 days ( 9 ). Early improvement in 
liver function with corticosteroid therapy is strongly associated 
with a marked decrease in short-term mortality. Th is improvement 
can be assessed by using the Lille Model (LM), which includes a 
measurement of response to treatment on day 7 of corticosteroid 
therapy ( 10 ). Almost 40% of patients with SAH are classifi ed as 
non-responders to corticosteroids according to the originally vali-
dated CUV>0.45, which is associated with a 6-month survival as 
low as 25% and dictates discontinuation of prednisolone owing 
to lack of therapeutic benefi t ( 11 ). However, this means that LM 
assessment requires at least 7 days of high-dose corticosteroids, 
increasing length of stay and related health-care costs. Also, non-
response to corticosteroids is highly predictive of sepsis, and it 
is tempting to hypothesize that prednisolone treatment further 
increases the risk of infection ( 2,12 ). Th is indicates the need 
for a prediction tool that identifi es patients at high risk for 
complications or mortality at an earlier stage from the start of 
corticosteroids.
 Early identifi cation of response to corticosteroid treatment 
is utterly important, allowing prediction of a complicated SAH 
course and survival and avoiding unnecessary treatment that 
might further aggravate prognosis. Th erefore, we aimed to 
evaluate LM performance at day 4 (LM4) in comparison with 
LM at day 7 (LM7) as an earlier predictor of response to cor-
ticosteroid therapy and its performance to predict survival in 
patients with SAH.
 METHODS
 Th e present study is a retrospective analysis of a multinational 
cohort of patients admitted with clinically SAH from January 
2010 to May 2015 at the University of Arkansas for Medical 
Sciences (United States); Liver Unit, Hospital Clinic, Barcelona 
(Spain); and Hospital das Clinicas, Faculty of Medicine Uni-
versity of São Paulo (Brazil). Th e study protocol received prior 
approval from the corresponding Institutional Review Board. All 
consecutive patients aged >18 years admitted with SAH based 
on a (1) DF≥32 (2), recent onset of jaundice (<12 weeks) (3), 
history of excessive alcohol consumption, and (4) suggestive 
liver chemistries were included. Data were obtained from the 
electronic medical records from each participating institution. 
Subjects without documentation of alcohol consumption of at 
least 40 g/day of alcohol prior to admission ( 13 ), patients with 
hepatocellular carcinoma, or other concomitant liver disorders 
were excluded.
 Clinical and biological data
 Demographic, clinical and biochemical data were recorded on 
admission: age, sex, alcohol intake (g/day), body mass index, 
white blood cell count, creatinine, aminotransferases (alanine 
aminotransferase and aspartate aminotransferase), bilirubin, 
albumin, prothrombin time, and international normalized 
ratio. Biochemical data corresponding to treatment days 4 and 
7 in patients receiving corticosteroids were documented as 
well. Clinical complications present at admission or develop-
ing during hospitalization (hepatic encephalopathy, renal failure 
on admission, acute kidney injury [AKI] during hospitaliza-
tion, bacterial infection or gastrointestinal bleeding [GIB] were 
recorded. Renal failure on admission was defi ned as a creatinine 
≥1.5 mg/dl, as creatinine determination prior to hospitalization 
was not available in the majority of patients. Development of 
AKI during hospitalization was defi ned according to the recom-
mendations of the International Club of Ascites, and we defi ned 
systemic infl ammatory response syndrome (SIRS) according to 
the American College of Chest Physicians ( 14,15 ). We paid spe-
cial attention to the treatment received during hospitalization 
and the fi nal outcome at last follow-up visit available on elec-
tronic medical records.
 Diagnosis of SAH was made in patients who fulfi lled the follow-
ing criteria (1): history of excessive alcohol consumption up until 
the onset of jaundice and prior to admission (2); liver chemistry 
suggestive of AH with a DF≥32. In 95 (58%) cases, histological 
confi rmation was available, demonstrating hepatocellular damage 
(ballooning and Mallory bodies) and characteristic infl ammatory 
infi ltrate ( 16,17 ). Patients were treated in all centers as per cur-
rent standards of care ( 18 ). In order to timely screen for possible 
subclinical infections, all centers routinely performed chest X-ray, 
urinalysis, urine culture, blood culture, and ascitic fl uid cell count 
and culture (when clinically feasible) immediately aft er admis-
sion. Across, infection surveillance was performed on a case-by-
case basis and driven by clinical manifestations. Treatment with 
corticosteroids was contraindicated in cases with uncontrolled 
infection, sepsis, or uncontrolled GIB. All patients receiving 
prednisolone were given 40 mg on a daily dose for up to 28 days, 
according to response assessed by LM7. LM was calculated for all 
patients by using the calculator at  www.lillemodel.com . A patient 
with LM score >0.45 at day 7 was considered a non-responder and 
prednisolone was discontinued on day 8. We calculated LM for all 
patients at day 4 with the same calculator, using day 4 bilirubin 
instead of day 7. Baseline severity scores (DF, MELD, ABIC, and 
GAHS) were calculated for all the patients by using the calcula-
tors provided at  www.lillemodel.com .
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 Statistical analysis
 Th e primary end point of our study was all-cause mortality at 90 
days from hospital admission. Long-term survival was considered 
a secondary end point given the rate of patients expected to be 
lost during follow-up. Data were described as median (range) 
for continuous variables and number (%) for discrete variables. 
Mann–Whitney  U -test was used to compare continuous variables, 
whereas χ 2 or Fisher was used to compare proportions, as appro-
priate. Correlation between LM4 and LM7 was assessed with 
Cohen’s kappa coeffi  cient. In patients treated with corticosteroids, 
baseline characteristics showing a  P value <0.2 in 28- and 90-day 
mortality univariate analyses (or those with biological interest) 
were entered into backward stepwise multivariable logistic regres-
sion models in hierarchized manner to avoid over fi tting. Th e util-
ity of LM4 to predict 28-day and 90-day mortality was evaluated 
by calculating the area under the receiver operating characteris-
tics curve (AUROC). A model with an AUROC≥0.7 was consid-
ered clinically useful, showing at least good accuracy. Sensitivity, 
specifi city, positive predictive values and negative predictive value 
of LM4 and LM7 at diff erent CUV were calculated (including 
CUV from Youden method to maximize accuracy). Th e accuracy 
of LM4, LM7, MELD, ABIC, and GAHS to predict 28- and 90-day 
mortality was assessed by comparing AUROCs by the method of 
Hanley and McNeil. Survival estimations were performed using 
Kaplan–Meier curves and Cox proportional hazards models for 
both univariate and multivariable analyses. Patients lost to follow-
up were censored at the time of their last visit. In all compari-
sons, a two-sided  P <0.05 was considered statistically signifi cant. 
All analyses were performed using STATA version 12 (StataCorp, 
College Station, TX).
 RESULTS
 Patient characteristics
 A total of 260 patients with a DF≥32 on admission (43% with 
biopsy-proven AH) were included, out of which 163 (62.7%) were 
treated with corticosteroids, whereas the remaining 97 (37.3%) 
were deemed not optimal candidates for corticosteroid therapy 
and received pentoxifylline or supportive therapy ( Figure 1 ). 
Among the patients who did not receive corticosteroids, 63% had 
uncontrolled sepsis on admission, 12.5% had active GIB, 2.5% 
presented multiorgan failure, and in 22.5% a clear cause could not 
be identifi ed. Th e main baseline characteristics, severity scores, 
and in-hospital complications are shown in  Table 1 . Th e median 
age of the patients treated with corticosteroids was 48 (41–55) 
years, 67.5% were males, and median body mass index was 
26.6 kg/m 2 (23.2–30.1). Apart from patients receiving corticoster-
oids being slightly older, reporting less alcohol abuse, and having 
higher total bilirubin levels, there were no statistical diff erences 
compared with those who did not. On admission, 45 (36.3%) 
subjects receiving prednisolone fulfi lled criteria for SIRS, and 
GIB occurred in 34 (20.9%) during hospitalization, with no dif-
ferences when compared with patients not treated with corticos-
teroids. Hepatic encephalopathy manifested in 66 (40%) during 
hospitalization, and it was more frequently seen among patients 
receiving corticosteroids. Renal failure on admission was docu-
mented in 43 (26.4%) of the patients treated with corticosteroids, 
and AKI developed in 30/67 (44.8%) more as inpatients, with no 
diff erences between groups. Regarding severity scores at admis-
sion, only DF and ABIC were found to be higher in patients with 
corticosteroids, with no diff erences in MELD and GAHS when 
compared with patients without corticosteroids. LM4 and LM7 
did not diff er between patients treated or not with corticosteroids.
 Predictors of 28- and 90-day mortality
 Th e median follow-up for patients treated with corticosteroids 
was 119 days (25–474), and for patients without corticosteroids it 
was 60 days (11–416),  P =0.01. Overall 90-day mortality was 35.9% 
for patients receiving corticosteroids and 36.6% for those who did 
not ( P =0.916). Univariate predictors of 28- and 90-day mortality 
are summarized in  Table 2 . Among all demographic and clinical 
variables, only hepatic encephalopathy, GIB, and AKI predicted 
28-day mortality. Older age, GIB, renal failure on admission 
and AKI were signifi cantly associated with 90-day mortality. As 
for biochemical variables, elevated creatinine and international 
normalized ratio were signifi cantly associated with both 28- and 
90-day mortality; whereas elevated white blood cell count and 
bilirubin were signifi cantly associated with 28- or 90-day morta-
lity, respectively. Finally, all of the AH severity scores (including 
LM4) were associated with 28- and 90-day mortality in patients 
with SAH treated with corticosteroids.
 In the multivariate model, LM4 remained an independent pre-
dictor of mortality at 28 days (odds rato (OR) 25.4, (95% confi -
dence interval (CI) 5.1–126.8)),  P <0.001) and 90 days (OR 16.9, 
(95% CI 4.5–64.3),  P <0.001). Among the remaining variables 
tested in the univariate analysis, only the presence of GIB (OR 
4.7, (95% CI 1.8–13.3),  P <0.003) was an independent predictor of 
mortality at 28 days. GIB (OR 6.3, (95% CI 2.3–17.6),  P <0.001) and 
renal failure on admission (OR 2.5, (95% CI 1.0–6.3),  P =0.032) 
showed to be independent predictors of mortality at 90 days in 
multivariable analysis.
 Performance of LM4 and LM7 in predicting 28- and 90-day 
mortality
 We were able to evaluate LM4 in 153 (94%) and LM7 in 150 
(92%) of the patients who received corticosteroids. Th ere were 70 
(45.8%) non-responders by LM4 and 68 (45.3%) by LM7. When 
classifi ed as responders or non-responders according to LM4 and 
LM7 score >0.45, the 28-day mortality was 8% and 10% among the 
former and 34% and 32% among the latter,  P <0.001. At 90 days, 
mortality for responders according to LM4 and LM7 was 34% and 
35% and for non-responders it was 60% and 58%,  P <0.001.
 Overall, there was 91.1% of agreement between LM4 and LM7 
to predict response (κ =0.82,  P <0.001) in patients receiving pred-
nisolone. Th e AUROCs for all severity scores as predictors of 
28- and 90-day mortality are shown in  Table 3 . No signifi cant dif-
ferences were found in pairwise comparisons between AUROCs 
from diff erent models, and particularly there were no diff erences 
between the AUROC from LM4 (0.77 (95% CI, 0.66–0.88)) as an 
earlier predictor of corticosteroid response and that of LM7 (0.74 
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(95% CI 0.63–0.85),  P =0.406). Notably among 7 patients who 
were non-responder by day 4 and became responder by day 7, 
71% died. On the other hand, of the 6 patients who were respond-
ers by day 4 but not by day 7, only 50% died. Operational charac-
teristics of LM4 and LM7 to predict 28- and 90-day mortality are 
shown in  Table 4 . Apart from the original CUV of 0.45, we tested 
a more recently proposed CUV of 0.56 in both LM4 and LM7. 
Notably, Youden index identifi ed 0.45 as the most accurate CUV, 
therefore, we kept the original 0.45 cutoff  point for the remainder 
of analyses.
 LM4 and LM7 and long-term survival
 By using LM4, the 90 days and 1-year survival were signifi cantly 
higher for responders (<0.45) compared with non-responders 
(76% and 63% vs. 40% and 32%,  P <0.001), for patients receiving 
corticosteroids,  Figure 2a . Also. LM7 showed signifi cantly higher 
survival for responders at 90 days and 1-year (75 and 60% vs. 42 
and 35%,  P <0.001),  Figure 2b .
 On the multivariate Cox regression analysis, response by LM4 
(<0.45) was associated with improved survival, with a hazard 
ratio (HR) 0.33 (95% CI; 0.19–0.56,  P <0.001). GIB with an 
HR 4.3 (95% CI; 2.5–7.7,  P <0.001) and renal failure on admis-
sion with an HR 1.9 (95% CI; 1.1–3.2,  P =0.19) were the only 
covariables that independently predicted decreased long-term 
survival.
 DISCUSSION
 Research interest in AH has gained momentum over the past few 
years. As SAH has a high mortality in the short term, the rational 
use of existing therapies or identifi cation of novel ones has become 
a priority. A recent randomized controlled trial by Th urz  et al. ( 9 ) 
that included 1053 patients with SAH, prednisolone showed only 
a modest trend toward improved survival at 28 days. Its use might 
increase fungal and bacterial infections, increasing the mortality 
risk in subjects with already poor prognosis. In the case of cor-
ticosteroids, rules and scores to abide to the  primum non nocere 
principle have taken great relevance. Among the available scores 
to identify and prognosticate SAH, only the LM proposed by Lou-
vet  et al. ( 10 ) takes into account the impact of treatment upon 
patient survival, allowing a timely termination of corticoster-
oids with the aim of preventing further complications that could 
negatively aff ect survival ( 10,19 ). However, calculation of the LM 
requires availability of biochemical data at day 7 of prednisolone 
therapy. Our study demonstrates that using LM4 is as accurate 
as the widespread LM that is currently applied on day 7 (LM7), 
with an agreement of 91%, and it has the potential of increasing 
safety through earlier termination of corticosteroids. Moreover, as 
shown in our AUROC analysis, LM4 can predict 28- and 90-day 
mortality in SAH patients receiving corticosteroids as accurately 
as LM7 and any of the other existing prognostic scores (i.e., 
Maddrey’s DF, MELD, ABIC, and GAHS). Although re-calculation 
Patients admitted with
SAH
n = 260
Inclusion criteria:
•  Maddrey’s DF >32
•  Jaundice <12 weeks
•  Long-standing alcoholism
•  Suggestive liver chemistries
Treated with
corticosteroids 
n = 163
Treated with PTX or
supportive treatment
n = 97
Not eligible for corticosteroid therapy
•  Uncontrolled sepsis
   n = 61 patients
•  Active gastrointestinal bleeding
   n = 12 patients
•  Multiorgan failure
   n = 3 patients
•  No information
   n = 21 patients
Lille Model 7
n = 150
Lille Model 4
n = 153
<0.45
n = 83
≥0.45
n = 70
<0.45
n = 82
≥0.45
n = 68
 Figure 1 .  Flow chart summarizing patient selection from the three participating centers. DF, discriminant function; PTX, pentoxifylline; SAH, severe alco-
holic hepatitis.
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with an intermediate risk of death. In a meta-analysis by Mathurin 
 et al. ( 11 ), patients were classifi ed according to the percentile dis-
tribution of their Lille score to avoid an arbitrary cutoff , identify-
ing three patterns of response (complete, intermediate, and null) 
with signifi cant diff erences in the risk of death. Results suggested 
that corticosteroids could positively impact survival in patients 
with complete (LM≤0.16) and intermediate response (LM>0.16–
<0.56), although novel therapies might bring further benefi t to 
the latter group. In contrast, null responders (LM≥0.56) have 
no benefi t from corticosteroids and may be considered for 
liver transplantation in highly selected cases, depending on age, 
of MELD and Maddrey’s DF at day 7 were reported to have good 
predictive accuracies (AUROCs>0.80) ( 20 ), their dynamic evolu-
tion (Δ MELD and Δ DF) has been reported to have less prognos-
tic power in comparison to LM7 and have not been validated as 
tools permitting early stopping of corticosteroids ( 10 ). Th erefore, 
earlier application of LM would spare 3 days of corticosteroids 
to patients with an LM4>0.45, potentially increasing safety and 
decreasing health-care costs and allowing considering these sub-
jects for alternative treatments, where available.
 It has been proposed that the use of a single cutoff  point in LM 
might be too restrictive and will not allow identifi cation of subjects 
 Table 1 .  Demographic and baseline characteristics 
 Variables  Total cohort,  n  =260  Corticosteroids,  n  =163  Without corticosteroids,  n  =97  P  value 
 Age (years) a  47 (40–55)  48 (41–55)  45 (35–51.5)  0.03 
 Gender, male b  184 (70.7)  110 (68)  74 (76.3)  0.131 
 BMI (kg/m 2 ) a  26.7 (24–30.1)  26.6 (23.2–30.1)  27.3 (25–30.1)  0.39 
 EtOH consumption (g/day) a  120 (100–180)  100 (90–165.7)  150 (100–308)  0.024 
 SIRS b  90 (41.1)  45 (36.3)  45 (47.4)  0.099 
 Follow-up days a  95 (19–435)  119 (25–474)  60 (11–416)  0.106 
 90-Day mortality a  90 (36.1)  56 (35.9)  34 (36.6)  0.916 
 Biochemical features a 
 WBC (K/μ l)  9.88 (6.42–14.67)  9.76 (6.7–14.5)  10.0 (5.9–14.98)  0.917 
 Platelets (K/μ l)  110 (77–177)  107 (77–163)  128 (77.5–189)  0.218 
 PT (s)  20.6 (17.6–24.7)  21.2 (18.8–26)  20.4 (17–24.1)  0.123 
 INR  1.76 (1.5–2.19)  1.78 (1.56–2.16)  1.7 (1.4–2.2)  0.131 
 Creatinine (mg/dl)  0.92 (0.7–1.79)  0.9 (0.69–1.6)  1.0 (0.7–1.98)  0.126 
 Bilirubin (mg/dl)  15.1 (7.7–25.7)  19.5 (9.9–27.1)  11.2 (5.6–21.3)  0.002 
 AST (IU/l)  152 (103–222)  146 (105–207)  172 (97.5–248)  0.207 
 ALT (IU/l)  49.5 (34–77)  51 (35–75)  48 (30–79)  0.839 
 Albumin (g/dl)  2.5 (2.1–3.0)  2.5 (2.2–3.0)  2.6 (2.0–3.0)  0.678 
 Complications b 
 Hepatic encephalopathy  124 (47.5)  66 (40.5)  58 (59.8)  0.003 
 Gastrointestinal bleeding  62 (23.9)  34 (20.9)  28 (28.9)  0.143 
 Severity scores a 
 Maddrey’s DF  54.4 (42.7–78.7)  64.1 (47.9–81.3)  55 (35.4–74.9)  0.011 
 MELD  22.9 (18.6–29.4)  22.7 (18.8–29.3)  23.5 (18–30.3)  0.885 
 ABIC  7.92 (6.9–9.08)  8.02 (7.1–9.12)  7.43 (6.42–8.96)  0.016 
 GAHS  9 (8–10)  9 (8–10)  9 (8–10)  0.203 
 Lille Model 4  0.41 (0.19–0.85)  0.39 (0.19–0.83)  0.69 (0.17–0.91)  0.318 
 Lille Model 7  0.37 (0.12–0.77)  0.36 (0.13–0.77)  0.44 (0.11–0.87)  0.98 
 ABIC, age, bilirubin, international normalized ratio and creatinine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DF, discrimi-
nant function; EtOH, alcohol; GAHS, Glasgow alcoholic hepatitis score; INR, international normalized ratio; MELD, model for end-stage liver disease; PT, prothrombin time; 
SIRS, Systemic infl ammatory response syndrome; WBC, white blood cell count. 
 a Data are presented as median and interquartile range 25–75. 
 b Data are presented as  n (%). 
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comorbidities, and addiction/social profi le ( 21–23 ). However, liver 
transplantation for patients with SAH is still controversial and, 
consequently, still far from gaining universal acceptance. In our 
study using the CUV>0.56 to defi ne response showed an inferior 
agreement at 84% (κ =0.68,  P <0.001) between LM4 and LM7. Such 
increase in the CUV did not translate into improved performance 
when compared with the standard 0.45 CUV, and it actually coin-
cided with the CUV statistically obtained to maximize sensitivity 
and specifi city. Th us our results support the use of 0.45 as the only 
CUV when applying LM4; however, it is not sensitive enough to 
identify subjects with SAH who will be in need for liver transplan-
tation.
 Patients with SAH developing infections have a higher mor-
tality, and this has also been proven to be true among those 
treated with corticosteroids ( 12 ). Louvet  et al. ( 2 ) demon-
strated that the probability of infection was lower in respond-
ers (LM<0.45) than in no responders (LM>0.45): 11% vs. 43%, 
with a median time for infection development of 14 days. Th is 
suggests that earlier discontinuation of corticosteroids might 
contribute to improved outcomes in non-responders by limit-
ing immunosuppression exposure. Although infections during 
index hospitalization and the presence of SIRS on admission 
were signifi cant predictors of 90-day mortality in our uni-
variate analysis, they were not independent risk factors in the 
 Table 2 .  Univariate analysis on predictors of 28- and 90-day mortality in patients treated with corticosteroids 
 Variable  28-Day status  P  value  90-Day status  P  value 
  Alive  Death   Alive  Death  
 Age (years) a  47 (39–53)  50 (46–56)  0.07  46 (39–52)  49 (42–56)  0.031 
 Gender, male b  84 (70)  20 (67)  0.72  70 (65.4)  37 (34.6)  0.612 
 BMI (kg/m 2 ) a  26 (23.2–30.1)  27.3 (25–29.4)  0.34  26.1 (23.2–30)  27.5 (24.9–32.3)  0.144 
 SIRS b  36 (36)  7 (46)  0.44  13 (30.9)  29 (69)  0.325 
 Hepatic encepha-
lopathy b 
 38 (32)  18 (60)  0.004  27 (44.3)  34 (55.7)  0.081 
 Gastrointestinal 
bleeding b 
 18 (15)  12 (40)  0.002  11 (33.3)  22 (66.7)  <0.001 
 Renal failure b  20 (17)  18 (60)  <0.001  15 (15)  23 (41.1)  <0.001 
 AKI b  20 (39)  7 (70)  0.07  13 (43.3)  17 (56.7)  0.030 
 Biochemical features a 
 WBC (K/μ l)  9.4 (6.3–13.9)  13.0 (8.4–17.9)  0.003  9.2 (6.1–14.0)  11.0 (7.7–15.4)  0.215 
 Platelets (K/μ l)  111 (77–183)  124 (82–192)  0.263  109 (77–175)  112 (78–182)  0.803 
 INR  1.7 (1.5–2.0)  2.0 (1.6–2.5)  0.004  1.7 (1.5–1.9)  1.9 (1.6–2.5)  0.002 
 Creatinine (mg/dl)  0.9 (0.7–1.3)  1.8 (0.9–3.7)  <0.001  0.8 (0.6–1.2)  1.4 (0.8–3.0)  0.003 
 Bilirubin (mg/dl)  13.9 (7.3–21.8)  22.5 (10.0–30.1)  0.08  12.7 (6.0–19.7)  22.5 (10.0–30.0)  0.045 
 AST (IU/l)  153 (107–208)  147 (99–234)  0.155  160 (110–216)  145 (96–241)  0.058 
 ALT (IU/l)  48 (34–69)  60 (38–92)  0.140  48 (32–70)  55 (36–83)  0.635 
 Albumin (g/dl)  2.6 (2.2–3.0)  2.5 (2.0–2.8)  0.736  2.6 (2.3–3.0)  2.3 (2.0–2.8)  0.082 
 Severity scores a 
 Maddrey’s DF  53 (39–68)  75 (58–98)  0.002  52.8 (37.6–67)  77 (55.4–108)  <0.001 
 MELD  22 (18–25)  33 (25–40)  <0.001  21.6 (17.5–24.7)  29.2 (21–37)  <0.001 
 ABIC  7.6 (6.7–8.5)  9.6 (8.2–10.9)  <0.001  7.36 (6.56–8.37)  8.74 (7.81–10–1)  <0.001 
 GAHS  8 (8–10)  10 (8–11)  0.01  8 (7–10)  10 (9–10)  0.003 
 Lille Model 4  0.36 (0.15–0.72)  0.89 (0.52–0.96)  <0.001  0.28 (0.13–0.65)  0.80 (0.39–0.95)  <0.001 
 Lille Model 7  0.30 (0.09–0.62)  0.89 (0.37–0.98)  <0.001  0.21 (0.08–0.59)  0.75 (0.35–0.97)  <0.001 
 ABIC, age, bilirubin, international normalized ratio and creatinine; AKI, acute kidney injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body 
mass index; DF, discriminant function; GAHS, Glasgow alcoholic hepatitis score; INR, international normalized ratio; MELD, model for end-stage liver disease; SIRS, 
Systemic infl ammatory response syndrome; WBC, white blood cell count. 
 a Data are presented as median and interquartile range 25–75. 
 b Data are presented as  n (%). 
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initially excluded owing to higher rate of complications (renal 
failure and infections) and mortality. However, this was mainly 
based on the lack of eff ective therapies for GIB. Much has 
changed since the initial trials, now we have eff ective treatment 
for most cases of upper GIB, including endoscopic band liga-
tion or transjugular intrahepatic porto-systemic shunt ( 26,27 ). 
However, the characteristics and outcomes of patients with GIB 
and SAH have not been well described. Rudler  et al. ( 12 ) con-
ducted a retrospective analysis of 105 patients of which 47 were 
admitted with SAH and GIB and compared with 58 with SAH 
without GIB. Survival was not signifi cantly diff erent (73.9% and 
69.9%), and interestingly, subjects with GIB were less prone to 
develop infections. Development of infection aft er starting cor-
ticosteroids, LM>0.45, and high MELD score were independent 
risk factors of poor survival ( 12 ). Th e diagnosis of SAH might 
have been overestimated in that study as DF is not a diagnostic 
tool and liver biopsy fi ndings are not specifi c. In our study, GIB 
was an independent risk factor for 28- and 90-day mortality and 
long-term survival together with response by day 4 as assessed 
by LM4. We did not diff erentiate between GIB present on 
multivariable analysis. Louvet  et al. ( 2 ) had similar fi ndings 
when prospectively evaluating 254 subjects with SAH, where at 
fi rst glance, infection was considered a major factor contribut-
ing to death, but it ended up not being an independent prognos-
tic factor, as early response to therapy was more important for 
predicting both survival and infection. As part of the standard 
of care in all patients with SAH, we routinely obtain blood and 
urine (±ascitic fl uid) cultures, provide prophylactic antibiotics 
during bleeding, and have a low threshold to start antibiotics 
when early clinical signs of infection are noted (i.e., pathologi-
cal urinalysis). Variations in the infections surveillance protocol 
during and aft er index admission among centers, as well as the 
lack of SIRS data during hospitalization, in our sample might 
explain discordant results.
 European Association for the Study of Liver and American 
Association for the Study of Liver Disease guidelines specify that 
patients with SAH and recent episode of upper GIB or renal fail-
ure are not ideal candidates for prednisolone treatment ( 24,25 ). 
Th e reason for excluding patients with recent GIB is based on 
clinical trials performed in 1970s and 1980s where they were 
 Table 3 .  Accuracy of severity scores to predict 28- and 90-day mortality 
 Variable  28-Day mortality  90-Day mortality 
  AUROC  95% CI  P  value a  AUROC  95% CI  P  value a 
 Lille Model 4  0.77  0.66–0.88  0.406  0.77  0.69–0.84  0.706 
 Lille Model 7  0.74  0.63–0.85   0.75  0.67–0.84  
 Maddrey’s DF  0.80  0.64–0.96  0.649  0.79  0.66–0.92  0.769 
 ABIC  0.80  0.72–0.89  0.307  0.73  0.67–0.80  0.51 
 MELD  0.76  0.65–0.88  0.863  0.67  0.57–0.77  0.106 
 GAHS  0.75  0.58–0.92  0.232  0.72  0.61–0.81  0.227 
 ABIC, age, bilirubin, international normalized ratio and creatinine; AUROC, area under receiver operational curve; CI, confi dence interval; DF, discriminant function; 
GAHS, Glasgow alcoholic hepatitis score; MELD, model for end-stage liver disease. 
 a Represents comparison of LM4 with the other severity scores. 
 Table 4 .  Operational characteristics of Lille Model at days 4 and 7 
 Variable  Time  CUV  Sensitivity  Specifi city  PPV  NPV 
 Lille Model 4  28 days  >0.45  79%  63%  34%  92% 
   >0.56  71%  67%  33%  90% 
 Lille Model 7   >0.45  71%  62%  32%  90% 
   >0.56  64%  68%  33%  88% 
 Lille Model 4  90 days  >0.45  70%  69%  56%  80% 
   >0.56  60%  60%  72%  76% 
 Lille Model 7   >0.45  65%  68%  53%  78% 
   >0.56  55%  29%  53%  74% 
 CUV, cutoff value; NPV, negative predictive value; PPV, positive predictive value. 
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admission or during hospitalization. Th ese might suggest that 
the presence of GIB on admission as long as patients receive 
adequate treatment should not be contraindication for steroid 
therapy, and measures should be taken to prevent the develop-
ment of GIB during hospitalization.
 Presence of SIRS on admission has been shown in previous 
reports to be a major predictor of multiorgan failure and death 
in AH ( 28 ). Infections during hospitalization, especially aft er 
starting treatment with corticosteroids, but not on admission, are 
associated with higher mortality ( 2,28 ). Development of nosoco-
mial infections is also associated with AKI and reduced survival; 
hence, the earlier application of LM will allow less exposure to 
corticosteroids in already high-risk population. Renal failure and 
development of AKI has been linked to infections and to reduced 
survival in SAH ( 29 ). In our study, SIRS and infections were not 
associated directly with 90-day mortality. Th is might be in rela-
tion to the retrospective nature of the design. However, we dem-
onstrated that the presence of renal failure on admission was an 
independent risk factor associated with increased 90-day mortal-
ity. In the present study, AKI was also a predictor of short-term 
mortality; however, it was not independently associated in the 
multivariable analysis owing to the small number of subjects with 
available information.
 Th e present study has some limitations, including its retro-
spective nature. Only 95 (58%) of the patients treated with cor-
ticosteroids had a confi rmatory liver biopsy. However, our study 
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 Figure 2 .  Kaplan-Meier survival analysis according to cutoff of the Lille Model, ( a ) LM4, Lille Model at day 4, ( b ) Lille Model at day 7.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Severe alcoholic hepatitis is associated with signifi cant 
morbidity and early mortality that can attain 50–75%. 
 ✓  Early improvement in liver function with corticosteroid 
therapy is associated with a decrease in short-term 
mortality. 
 ✓  Response to corticosteroid therapy is determined by Lille 
Model on day 7. 
 ✓  Up to 40% of patients with alcoholic hepatitis are 
non-responders, increasing risk of infections with a 
6-month survival as low as 25%. 
 WHAT IS NEW HERE 
 ✓  Lille Model on day 4 is as good as Lille Model on day 7 to 
predict response to corticosteroids in patients with severe 
alcoholic hepatitis. 
 ✓  Lille Model on day 4 is an independent predictor of 
28- and 90-day mortality. 
 ✓  Calculation of Lille Model on day 4 will allow decreased 
exposure to corticosteroids in non-responders. 
 ✓  This novel strategy might decrease risk of nosocomial infec-
tions and health-care costs in severe alcoholic hepatitis. 
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represents a multinational cohort refl ecting the experience of 
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between day 4 and 7, we were not able to prove that patients 
with an earlier response show further improvement in their prog-
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prospectively.
 Discovering an accurate biomarker capable of identifying 
high-risk patients who will fail to respond to corticosteroids is 
of utter importance. In the absence of such a biomarker, opti-
mizing the use of current available predictive models is a pri-
ority in SAH. Our results showed that LM4 is as good as LM7 
to determine response to corticosteroids and for prediction of 
28- and 90-day mortality in patients with SAH. Th e use of LM4 
instead of LM7 has various benefi ts: it would decrease exposure 
to corticosteroids, and spare up to 3 days of hospitalization in 
clinically stable patients. Th ese benefi ts should translate into a 
decreased risk for infections, particularly nosocomial infections, 
and indirectly improve outcomes in this population. Without 
a doubt, this strategy would save costs to health-care systems 
worldwide. However, prospective studies systematically study-
ing the frequency and type of infections in patients with early 
dismissal from hospital aft er LM4 are needed, in parallel with a 
cost-eff ectiveness analysis.
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